

This is a repository copy of *Nonchromosomal birth defects and risk of childhood acute leukemia : An assessment in 15 000 leukemia cases and 46 000 controls from the Childhood Cancer and Leukemia International Consortium.*

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/205391/>

Version: Accepted Version

Article:

Lupo, Philip J, Chambers, Tiffany M, Mueller, Beth A et al. (24 more authors) (2023) Nonchromosomal birth defects and risk of childhood acute leukemia : An assessment in 15 000 leukemia cases and 46 000 controls from the Childhood Cancer and Leukemia International Consortium. *International Journal of Cancer*. ISSN 1097-0215

<https://doi.org/10.1002/ijc.34720>

Reuse

This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the authors for the original work. More information and the full terms of the licence here:

<https://creativecommons.org/licenses/>

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



Non-chromosomal birth defects and risk of childhood leukemia: an assessment in 15,000 leukemia cases and 46,000 controls from the Childhood Cancer and Leukemia International Consortium

Journal:	<i>International Journal of Cancer</i>
Manuscript ID	Draft
Wiley - Manuscript type:	Research Article
Date Submitted by the Author:	n/a
Complete List of Authors:	<p>Lupo, Philip; Baylor College of Medicine, Pediatrics Chambers, Tiffany; Baylor College of Medicine Department of Pediatrics Mueller, Beth; Fred Hutchinson Cancer Research Center, Public Health Sciences Division; University of Washington Department of Epidemiology Clavel, Jacqueline; INSERM, UMR-S1153 Dockerty, John; University of Otago, Preventive & Social Medicine Doody, David ; Fred Hutchinson Cancer Research Center Erdmann, Friederike; International Agency for Research on Cancer; Johannes Gutenberg University Mainz Ezzat, Sameera; Menoufia University National Liver Institute Filippini, Tommaso; University of Modena and Reggio Emilia, Department of Biomedical, Metabolic and Neural Sciences; University of California Berkeley School of Public Health Hansen, Johnni; Danish Cancer Society, Insitute of Cancer Epidemiology;</p> <p>Heck, Julia; University of North Texas College of Health and Public Services Infante-Rivard, Claire; McGill University, Faculty of Medicine, Epidemiology, Biostatistics and Occupational Health Kang, Alice Y; University of California, Berkeley, School of Public Health Magnani, Corrado; University of Piemonte Orientale, Department of Translational Medicine, Unit of Medical Statistics and Cancer Epidemiology Malagoli, Carlotta ; Università degli Studi di Modena e Reggio Emilia Dipartimento di Scienze Biomediche Metaboliche e Neuroscienze Metayer, Catherine; University of Berkeley, School of Public Health Bailey, Helen; Curtin University; Telethon Kids Institute Mora, Ana M; University of California Berkeley School of Public Health Ntzani , Evangelia ; University of Ioannina Department of Hygiene and Epidemiology; Brown University School of Public Health Petridou, Eleni; National and Kapodistrian University of Athens, Department of Hygiene, Epidemiology and Medical Statistics; Hellenic Society for Social Pediatrics and Health Promotion Pombo-de-Oliveira, Maria; Instituto Nacional de Cancer, Pediatric Hematology-Oncology Program rashed, wafaa; Children's Cancer Hospital Egypt 57357, ; CCHE-57357 Roman, Eve; University of York, Health Sciences; University of York</p>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

	Schüz, Joachim; International Agency for Research on Cancer, Section of Environment Wesseling, Catharina; Karolinska Institutet, Unit of Occupational Medicine, Institute of Environmental Medicine Spector, Logan; University of Minnesota, Department of Pediatrics; Scheurer, Michael; Baylor College of Medicine, Dan L Duncan Cancer Center
Key Words:	Epidemiology, childhood leukemia, birth defects, acute lymphoblastic leukemia, acute myeloid leukemia



1
2
3 **Non-chromosomal birth defects and risk of childhood leukemia: an assessment in 15,000**
4 **leukemia cases and 46,000 controls from the Childhood Cancer and Leukemia**
5 **International Consortium**
6
7
8
9

10
11 Philip J. Lupo¹, Tiffany M. Chambers¹, Beth A. Mueller^{2,3}, Jacqueline Clavel⁴, John D. Dockerty⁵,
12 David R. Doody², Friederike Erdmann^{6,7}, Sameera Ezzat^{8*}, Tommaso Filippini^{9,13}, Johnni
13 Hansen¹⁰, Julia E. Heck¹¹, Claire Infante-Rivard¹², Alice Y. Kang¹³, Corrado Magnani¹⁴, Carlotta
14 Malagoli⁹, Catherine Metayer¹³, Helen D. Bailey^{15,16}, Ana M. Mora¹⁷, Evangelia Ntzani^{18,19}, Eleni
15 Th Petridou^{20,21}, Maria S. Pombo-de-Oliveira²², Wafaa M. Rashed²³, Eve Roman²⁴, Joachim
16 Schüz⁶, Catharina Wesseling²⁵, Logan G. Spector²⁶, Michael E. Scheurer¹
17
18
19
20
21
22
23
24
25

26 1 Department of Pediatrics, Division of Hematology-Oncology, Baylor College of Medicine,
27 Houston, Texas, USA
28

29 2 Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle,
30 Washington, USA
31
32

33 3 Department of Epidemiology, University of Washington, Seattle, Washington, USA
34

35 4 CRESS, UMR-S1153, INSERM, Paris-Descartes University, Villejuif, France
36

37 5 Department of Preventive and Social Medicine, University of Otago, Dunedin, New Zealand
38

39 6 International Agency for Research on Cancer (IARC), Section of Environment and Lifestyle
40 Epidemiology, Lyon, France
41
42

43 7 Division of Childhood Cancer Epidemiology, Institute for Medical Biostatistics, Epidemiology
44 and Clinical Research, Department of Pediatrics, Informatics (IMBEI), Johannes Gutenberg
45 University of Minnesota, Mainz, Germany
46
47
48

49 8 Department of Epidemiology and Preventive Medicine, NLISSI Collaborative Research
50 Center, National Liver Institute, Menoufia University, Cairo, Egypt
51
52

53 9 CREAGEN Environmental, Genetic and Nutritional Epidemiology Research Center,
54
55
56
57
58
59
60

1
2
3 Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio
4 Emilia, Modena, Italy

5
6
7 10 Danish Cancer Society Research Center, Copenhagen, Denmark

8
9 11 College of Health and Public Service, University of North Texas, Denton, Texas, USA

10
11 12 Department of Epidemiology, Biostatistics and Occupational Health, Faculty of Medicine,
12 McGill University, Montreal, QC, Canada

13
14 13 School of Public Health, University of California, Berkeley, Berkeley, California, USA

15
16 14 Dipartimento di Medicina Traslazionale, Università del Piemonte Orientale, Piemonte,
17 Novara, Italy

18
19 15 Curtin Medical School, Faculty of Health Sciences, Curtin University, Perth, Australia

20
21 16 Telethon Kids Institute, The University of Western Australia, Nedlands, Australia

22
23 17 Center for Environmental Research and Community Health (CERCH), School of Public
24 Health University of California, Berkeley, Berkeley, California, USA

25
26 18 Department of Hygiene and Epidemiology, Medical School, University of Ioannina, Ioannina,
27 Greece

28
29 19 Center for Evidence Synthesis in Health, Policy and Practice, Center for Research Synthesis
30 in Health, School of Public Health, Brown University, Providence, RI, United States

31
32 20 Department of Hygiene, Epidemiology and Medical Statistics, Medical School, National and
33 Kapodistrian University of Athens, Athens, Greece

34
35 21 Hellenic Society for Social Pediatrics and Health Promotion, Athens, Greece

36
37 22 Research Center, Instituto Nacional de Cancer, Rio de Janeiro, Brazil

38
39 23 Research Department, Children's Cancer Hospital Egypt, Cairo, Egypt

40
41 24 Epidemiology and Cancer Statistics Group, Department of Health Sciences, University of
42 York, United Kingdom

43
44 25 Unit of Occupational Medicine, Institute of Environmental Medicine, Karolinska Institutet,
45 Stockholm, Sweden

1
2
3 26 Division of Epidemiology and Clinical Research, Department of Pediatrics, University of
4
5 Minnesota, Minneapolis, Minnesota, USA

6
7 *Posthumous author
8
9

10
11 **Manuscript Type:** Cancer Epidemiology
12
13

14
15 **Key Words:** Epidemiology, childhood leukemia, birth defects, acute lymphoblastic leukemia,
16
17 acute myeloid leukemia
18

19
20 **Abbreviations:** ALL: acute lymphoblastic leukemia; AML: acute myeloid leukemia; CI:
21
22 confidence interval; CLIC: Childhood Cancer and Leukemia International Consortium; FDR:
23
24 false discovery ratio; NBDPN: National Birth Defects Prevention Network; OR: odds ratio
25

26
27 **Conflict of interest:** The authors declare no potential conflicts of interest

28
29 **Correspondence to:** Philip J. Lupo in the Department of Pediatrics, Baylor College of Medicine,
30
31 Houston, Texas, USA (philip.lupo@bcm.edu)
32
33

34 35 **Novelty and Impact**

36
37 Little is known about the potential etiologic role non-chromosomal birth defects have on
38
39 childhood leukemia risk. Therefore, we sought to identify associations between leukemia and
40
41 non-chromosomal birth defects in a pooled cohort from studies participating in the Childhood
42
43 Cancer and Leukemia International Consortium. Certain birth defects were strongly associated
44
45 with increased leukemia risk. These associations could point to novel genetic and environmental
46
47 factors associated with birth defects that could also increase leukemia susceptibility.
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Although recent studies have demonstrated associations between non-chromosomal birth defects and several pediatric cancers, less is known about their role on childhood leukemia susceptibility. Using data from the Childhood Cancer and Leukemia International Consortium, we evaluated associations between non-chromosomal birth defects and childhood leukemia. Pooling data from 18 questionnaire-based studies and three registry-based studies across 13 countries, we used multivariable logistic regression models to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for the association between a spectrum of birth defects and leukemia. Our analyses included acute lymphoblastic leukemia (ALL, n=13,115) and acute myeloid leukemia (AML, n=2,120) cases, along with 46,172 controls. We used the false discovery rate to account for multiple comparisons. In the questionnaire-based studies, the prevalence of birth defects was 5% among cases versus 4% in controls, whereas, in the registry-based studies, the prevalence was 11% among cases versus 7% in controls. In pooled adjusted analyses, there were several notable associations, including: 1) digestive system defects and ALL (OR=2.70, 95% CI: 1.46-4.98); 2) congenital anomalies of the heart and circulatory system and AML (OR=2.86, 95% CI: 1.81-4.52); and 3) nervous system defects and AML (OR=4.23, 95% CI: 1.50-11.89). Effect sizes were generally larger in registry-based studies. Overall, our results could point to novel genetic and environmental factors associated with birth defects that could also increase leukemia susceptibility. Additionally, differences between questionnaire- and registry-based studies point to the importance of complementary sources of birth defect phenotype data when exploring these associations.

Introduction

Leukemia accounts for around a third of all cancers diagnosed in individuals younger than 15 years of age, with acute lymphoblastic leukemia (ALL) as the most common (~75%) subtype and acute myeloid leukemia (AML) as the second most common (~15%).^{1, 2} While five-year survival for children with ALL and AML has improved over the past several decades approaching 90% in some settings,^{3, 4} survival remains poor for those with relapsed disease. Furthermore, survivors experience an excess risk of adverse health outcomes related to their cancer diagnosis and treatment.⁵ Despite the incidence and clinical importance of these malignancies, outside of the approximately 5% of cases that are due to genetic syndromes, a majority of cases are of unknown etiologies.⁶

One of the strongest genetic risk factors for developing ALL and AML is being born with trisomy 21 (i.e., Down syndrome).⁷⁻⁹ Compared to their contemporaries, children with Down syndrome are 20-times more likely to develop ALL and 200-times more likely to develop AML, respectively.¹⁰ This and certain other chromosomal anomalies are well-established risk factors for ALL and AML; however, much less is known about the potential etiologic role of non-chromosomal birth defects, which affect approximately 6% of pregnancies worldwide.¹¹

There is strong evidence indicating non-chromosomal birth defects are associated with a range of pediatric solid tumors.^{10, 12-24} However, associations between specific non-chromosomal birth defects and leukemia are less clear. Therefore, we sought to comprehensively evaluate the association between non-chromosomal birth defects and leukemia using data from the Childhood Cancer and Leukemia International Consortium (CLIC).²⁵ This is a consortium of leukemia-focused questionnaire- and registry-based case-control studies (which is now open to other pediatric tumors as well). CLIC was established in 2007 with the goal of overcoming the limitations of single epidemiological studies and allowing the assessment of relatively infrequent potential risk factors, including specific non-chromosomal birth defects.

Methods

Study Subjects

Comprehensive descriptions of CLIC have been published previously.²⁵⁻³¹ Data for our pooled analyses were provided from 18 case-control and three registry linkage studies in 13 countries. Each eligible study provided both birth defect and leukemia data. Depending on the study design, questionnaires, hospital records, birth records, population-based birth defect registries, and cancer registries were used to identify cases and select controls. Children born with recognized chromosomal anomalies and/or single gene disorders (as defined below) were excluded from this assessment. Our overall study population consisted of 46,172 controls and 15,235 acute leukemia cases (ALL n=13,115 and AML n=2,120). In separate analyses, we evaluated all cases (ALL or AML) diagnosed at ≤ 12 months of age (i.e., infant leukemia, n=1,152). Prior to contributing data, all studies were approved by their respective institutional review boards or ethics committees.

Birth Defects Diagnoses

Birth defect diagnoses were provided by: 1) diagnosis name; 2) codes using the Eighth, Ninth, or Tenth Revisions of the World Health Organization's International Classification of Diseases, Clinical Modification (i.e., ICD-8, ICD-9, and ICD-10); or 3) codes using the Western Australian Register of Developmental Anomalies (WARDA).³² All diagnoses were converted to the Centers for Disease Control and Prevention (CDC) modification of the British Paediatric Association Classification of Diseases (BPA) using coding-specific crosswalks obtained from the National Birth Defects Prevention Network (NBDPN) and WARDA. For this assessment, we evaluated major birth defects included as part of the NBDPN annual report or the National Birth Defects Prevention Study.^{33, 34}

Study Variables

In addition to data on birth defects and leukemia, the following variables were obtained from each study: child's sex, age at leukemia diagnosis (cases), age at study entry (controls) histological subtype, ALL immunophenotype, year of birth, birthweight, gestational age, child's race/ethnicity, plurality, as well as maternal age at child's birth and maternal education. Data were standardized across studies.

Statistical Methods

We used frequencies and percentages to describe demographic and clinical characteristics among the study population. We used logistic regression models to calculate odds ratios (OR) and 95% confidence intervals (CI) for each birth defect-leukemia combination, while adjusting for the following variables: study site, sex, birthweight (<2,500; 2,500-3,999; >3,999 grams), gestational age (preterm [<37 weeks]; term [\geq 37 weeks]), maternal age (<25; 25-29; 30-34; 35-39; \geq 40 years), birth year, and child's race/ethnicity (non-Hispanic White; non-Hispanic Black; Hispanic; and other). These variables were selected based on previous assessments and to be consistent with other studies evaluating associations between non-chromosomal birth defects and pediatric cancer.^{10, 26-31} However, unadjusted ORs and 95% CIs were also calculated and presented.

We first evaluated the associations between leukemia subtypes of interest (ALL, AML, and infant leukemia) and specific birth defects (e.g., ventricular septal defect), as well as larger birth defect groupings (e.g., congenital anomalies of the heart and circulatory system). Based on standard data suppression rules,¹⁰ our analyses were restricted to patterns where there were \geq 5 co-occurring cases. We used the false discovery rate (FDR) to account for multiple comparisons.³⁵ To evaluate the impact of differences in birth defect reporting, candidate associations were stratified by study design (i.e., questionnaire- vs. registry-based studies). Lastly, we evaluated the association between number of birth defects (0 defects, 1 defect, \geq 2

1
2
3 defects) and leukemia risk. All statistical analyses were performed using Stata 15.0 (StataCorp
4 LP, College Station, TX).
5
6
7
8

9 **Results**

10
11 Overall, there were 46,172 controls and 15,235 cases: 13,115 ALL; 2,120 AML; 1,152
12 infant (Table 1). The distribution of demographic characteristics across cases and controls was
13 largely consistent with some exceptions. Overall, the prevalence of non-chromosomal birth
14 defects was 5.8% in both cases and controls (Table 2). However, as described below, there
15 were some notable differences for ALL, AML, and infant leukemia by birth defect group and by
16 specific birth defects.
17
18
19
20
21
22
23
24
25

26 *Non-Chromosomal Birth Defects and ALL*

27
28 Among the 10 non-chromosomal birth defect groups evaluated (Table 2), three were
29 significantly associated with ALL in adjusted models after correcting for multiple comparisons: 1)
30 congenital anomalies of the heart and circulatory system (OR=1.46, 95% CI: 1.10-1.95); 2)
31 congenital anomalies of the digestive system (OR=2.70, 95% CI: 1.46-4.98); and 3) congenital
32 anomalies of the skin (OR=1.43, 95% CI: 1.11-1.85). While hypospadias was associated with
33 ALL (OR=2.12, 95% CI: 1.16-3.85), it was not statistically significant after correcting for multiple
34 comparisons ($p_{\text{FDR}}=0.066$). The only specific birth defect associated with ALL after correcting for
35 multiple comparisons was congenital cataracts (OR=18.62, 95% CI: 4.36-79.49, $p_{\text{FDR}}=0.002$).
36
37
38
39
40
41
42
43
44

45 To account for differences in birth defect reporting, associations were then stratified by
46 study design (i.e., questionnaire- vs. registry-based). The direction and magnitude of the effect
47 estimates were consistent for congenital anomalies of the digestive system and congenital
48 anomalies of the skin (Table 3). This was not the case for congenital anomalies of the heart and
49 circulatory system where the OR in questionnaire-based studies was 0.84 (95% CI: 0.55-1.28)
50 compared to 2.36 (95% CI: 1.66-3.34) in registry-based studies.
51
52
53
54
55
56
57
58
59
60

Non-Chromosomal Birth Defects and AML

Three non-chromosomal birth defect groups were significantly associated with AML in adjusted models after correcting for multiple comparisons (Table 2): 1) congenital anomalies of the nervous system (OR=4.23, 95% CI: 1.50-11.89); 2) congenital anomalies of the heart and circulatory system (OR=2.86, 95% CI: 1.81-4.52); and 3) congenital anomalies of the skin (OR=0.36, 95% CI: 0.18-0.70). The OR for congenital anomalies of the skin was <1.0, suggesting children with AML were less likely to have these non-chromosomal birth defects compared to controls. None of the specific birth defects with ≥ 5 co-occurring cases was significantly associated with AML.

When numbers were sufficient to conduct sensitivity analyses for AML stratified by study design, results were consistent in terms of direction of effect (Table 4); however, effect estimates from the registry-based studies were larger. For example, associations with congenital anomalies of the heart and circulatory system were stronger in registry-based studies (OR=5.39, 95% CI: 3.14-9.24) compared to questionnaire-based studies (OR=1.28, 95% CI: 0.61-2.67).

Non-Chromosomal Birth Defects and Infant Leukemia

While there were no significant associations between non-chromosomal birth defects and infant leukemia after correcting for multiple comparisons, there was a strong association with congenital anomalies of the digestive system and infant leukemia (OR=4.55, 95% CI: 1.06-19.62), which was stronger when evaluating effects in questionnaire-based studies (OR=7.31, 95% CI: 1.20-44.63) (data not shown). However, these associations were based on a small number of co-occurring cases ($n=6$). There were not enough observations to evaluate specific associations in registry-based studies.

Risk of Leukemia by Number of Birth Defects

While there was a significant p-for-trend when evaluating the association between increasing number of non-chromosomal birth defects and ALL ($p_{\text{trend}}=0.006$), the association was neither strong nor statistically significant for children with ≥ 2 defects ($OR_{\text{ALL}}=1.32$, 95% CI: 0.90-1.94; Table 5). For both AML and infant leukemia, risk was greater for children with ≥ 2 birth defects ($OR_{\text{AML}}=1.96$, 95% CI: 1.10-3.46 and $OR_{\text{infant leukemia}}=1.71$, 95% CI: 0.93-1.35) compared to children with 1 defect ($OR_{\text{AML}}=0.92$, 95% CI: (0.72-1.18 and $OR_{\text{infant leukemia}}=0.97$, 95% CI: 0.69-1.35) (Table 5).

Discussion

In this large assessment of leukemia risk among children with non-chromosomal birth defects, which included >15,000 cases and >46,000 controls, we report several birth defect-leukemia associations including: 1) congenital anomalies of the digestive system-ALL; 2) congenital cataracts-ALL; 3) anomalies of the skin-ALL; 4) congenital anomalies of the heart-ALL; 5) congenital anomalies of the heart-AML; and 6) congenital anomalies of the nervous system-AML. Several of our observations are consistent with previous findings,¹⁰ including anomalies of the skin-ALL and congenital anomalies of the heart and circulatory system-AML.

While these associations are notable, our study points to two important findings in relation to non-chromosomal birth defects and leukemia susceptibility. First, there are not as many associations reported for leukemia as with some solid tumors (e.g., germ cell tumors are associated with a larger spectrum of birth defects).^{10, 21} Second, associations are not as strong as reported for other pediatric cancers (e.g., neuroblastoma).^{10, 17, 19, 20} However, some of these differences could be due to the variability in birth defect reporting between questionnaire-based studies and registry-based studies.

In our assessment, the prevalence of birth defects was higher in registry-based studies compared to questionnaire-based studies. Additionally, birth defect-leukemia associations from

1
2
3 registry-based studies were generally stronger compared to questionnaire-based studies. This
4 suggests to the likelihood of underreporting in questionnaire-based studies, as well as the
5 potential for differential reporting. In fact, there are reported differences in birth defect reporting
6 across many modalities (e.g., birth certificates, questionnaires, active surveillance).³⁶⁻³⁹ Because
7 of that, it is important to leverage multiple sources of data when evaluating these conditions and
8 their impact on cancer risk. Future studies of leukemia risk in children with non-chromosomal
9 birth defects should utilize data from expanded registry linkages. Nevertheless, our assessment
10 yielded new insights regarding birth defect-leukemia associations.
11
12
13
14
15
16
17
18
19

20 We found generally consistent associations for congenital anomalies of the digestive
21 system and ALL (while not statistically significant, similar patterns were seen for AML and infant
22 leukemia); congenital cataracts and ALL; congenital anomalies of the nervous system and AML;
23 and congenital anomalies of the heart and circulatory system for both ALL and AML. These
24 observed associations could be due to a range of factors. First, each of these structural birth
25 defects is more common in children with Down syndrome.⁴⁰ Although we excluded children with
26 Down syndrome from this assessment, it is possible that genetic variation on chromosome 21
27 could explain the co-occurrence of these conditions, or that cases of Down syndrome were
28 misclassified.^{7, 41} Second, it is also possible that these associations could be due to other known
29 syndromes that were not diagnosed in these individuals. For example, children with Fanconi
30 anemia, an AML predisposition syndrome, are more likely to have heart and gastrointestinal
31 defects compared to unaffected children.⁴² Third, it is possible that these associations could
32 represent “yet-to-be-discovered” cancer predisposition syndromes or shared genetic effects
33 across phenotypes (i.e., pleiotropy) that could be leveraged to discover novel genetic variants
34 underlying the occurrence of both birth defects and leukemia.
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50

51 A largely unexplored potential explanation for the overlap between non-chromosomal
52 birth defects and leukemia, as well as other pediatric cancers, is the role of non-genetic *in utero*
53 factors and exposures that could lead to both phenotypes (e.g., maternal diabetes) or postnatal
54
55
56
57
58
59
60

1
2
3 exposures that children with birth defects are more likely to receive (e.g., diagnostic procedures
4 that involve radiation).²¹ However, outside of a recent assessment evaluating the impact of *in*
5 *vitro* fertilization (IVF) on the co-occurrence of birth defects and pediatric cancer, which reported
6 that IVF-exposed children were more likely to develop both birth defects and cancer compared
7 to naturally conceived children,⁴³ there have been few attempts to evaluate the role of various
8 exposures on the overlap between these conditions.
9
10
11
12
13
14

15
16 Our study must be considered in the light of certain limitations. First, and as noted, it is
17 possible that birth defects may have been incompletely ascertained. Our study relied separately
18 on self-reported birth defects (questionnaire-based studies) and independent assessment of
19 birth defects (registry-based studies). Each of these approaches has limitations.²¹ However, for
20 defects with sufficient numbers to evaluate associations by study design, the direction of effects
21 were largely consistent, with findings from registry-based studies being stronger. Also, while
22 incomplete ascertainment of birth defects may bias our effect estimates, most studies of birth
23 defects and cancer risk (independent of birth defect ascertainment method) have comparable
24 findings.²¹ Even in our large study, sample size issues or data availability limited our ability to
25 evaluate subtypes based on immunophenotype, cytogenetic features, or other genomic
26 characteristics. This could be particularly important as there is evidence that etiologic factors
27 differ by tumor characteristics.⁴⁴ Finally, an issue inherent in studies of birth defects and cancer is
28 that children diagnosed with cancer may undergo additional diagnostic scrutiny compared to
29 children without a malignancy, which results in the increased identification of birth defects in
30 cases compared to controls.¹⁰ However, previous assessments have indicated this is likely not a
31 driver of observed birth defect-pediatric cancer associations.¹⁰
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48

49 The present study has considerable strengths, most notably its large sample size
50 (>15,000 cases), which enabled us to evaluate specific non-chromosomal birth defects that
51 have not been included in previous assessments. Another strength of our assessment is the
52 inclusion of different study designs (questionnaire- versus registry-based) as well as leukemia
53
54
55
56
57
58
59
60

1
2
3 types (ALL, AML, and infant acute leukemia), which allowed us to conduct sensitivity analyses
4
5 to evaluate differences by case ascertainment method, helping us to confirm associations.
6
7 Lastly, as this is an international study, we included diverse populations from multiple settings
8
9 and geographical locations.
10

11 In conclusion, while associations between non-chromosomal birth defects and leukemia
12
13 risk were observed, they were not as numerous or strong as those reported for other less
14
15 common pediatric cancers. However, these findings contribute to our understanding of leukemia
16
17 risk. Specifically, future assessments could leverage associations related to the role of
18
19 anomalies of the heart, skin, and digestive system to evaluate the role of shared genetic effects
20
21 and non-genetic exposures, thereby yielding new insights into the overlap between non-
22
23 chromosomal birth defects and acute leukemia, as well as acute leukemia susceptibility in
24
25 general.
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Author Contributions

Philip J. Lupo: Conceptualization, Data curation, Funding acquisition, Investigation, Methodology, Project administration, Supervision, Validation, Visualization, Writing – original draft, and Writing – review & editing; **Tiffany M. Chambers:** Data curation, Formal analysis, Methodology, Visualization, Writing – original draft, and Writing – review & editing; **Beth A. Mueller:** Conceptualization, Investigation, Methodology, Resources, Supervision, Validation, and Writing – review & editing; **Jacqueline Clavel:** Methodology, Resources, Validation, and Writing – review & editing; **John D. Dockerty:** Methodology, Resources, Validation, and Writing – review & editing; **David R. Doody:** Resources, and Writing – review & editing; **Friederike Erdmann:** Methodology, Resources, and Writing – review & editing; **Sameera Ezzat:** Methodology, Resources, Validation, and Writing - review & editing; **Tommaso Filippini:** Resources, and Writing – review & editing; **Johnni Hansen:** Resources, and Writing – review & editing; **Julia E. Heck:** Methodology, Resources, Validation, and Writing – review & editing; **Claire Infante-Rivard:** Methodology, Resources, Validation, and Writing – review & editing; **Alice Y. Kang:** Funding acquisition, Project administration, Resources, and Writing – review & editing; **Corrado Magnani:** Methodology, Resources, Validation, and Writing – review & editing; **Carlotta Malagoli:** Methodology, Resources, Validation, and Writing – review & editing; **Catherine Metayer:** Funding acquisition, Methodology, Resources, and Writing – review & editing; **Helen D. Bailey:** Funding acquisition, Methodology, Resources, and Writing – review & editing; **Ana M. Mora:** Methodology, Resources, and Writing – review & editing; **Evangelia Ntzani:** Methodology, Resources, Validation, and Writing – review & editing; **Eleni Th Petridou:** Funding acquisition, Methodology, Resources, Validation, and Writing – review & editing; **Maria S. Pombo-de-Oliveira:** Methodology, Resources, Validation, and Writing – review & editing; **Wafaa M. Rashed:** Methodology, Resources, and Writing – review & editing; **Eve Roman:** Methodology, Resources, Validation, and Writing – review & editing; **Joachim Schüz:** Methodology, Resources, Validation, and Writing – review & editing; **Catharina Wesseling:**

1
2
3 Methodology, Resources, and Writing – review & editing; **Logan G. Spector:**

4
5 Conceptualization, Investigation, Methodology, Resources, Supervision, Validation, and Writing
6
7 – review & editing; **Michael E. Scheurer:** Conceptualization, Data curation, Investigation,
8
9 Methodology, Resources, Supervision, Visualization, and, Writing – review & editing
10
11

12 The work reported in the paper has been performed by the authors, unless clearly specified in
13
14 the text.
15
16
17
18
19

20 **Data Availability Statement**

21
22 Supporting data may be obtained by formal application to each of the participating Principal
23
24 Investigators and the relevant ethical and regulatory bodies. Further information is available
25
26 from the corresponding author upon request.
27
28
29
30
31

32 **Ethics Statement**

33
34
35 All participating studies were approved by relevant ethics committees or institutional review
36
37 boards.
38
39
40
41
42

43 **Acknowledgements**

44
45 **AUS-ALL:** The AUS-ALL consortium conducted the AUS-ALL study and the Telethon Kids
46
47 Institute (formerly Telethon Institute for Child Health Research; TICHR), University of Western
48
49 Australia, was the coordinating center. Bruce Armstrong (Sydney School of Public Health),
50
51 Elizabeth Milne (TICHR), Frank van Bockxmeer (Royal Perth Hospital), Michelle Haber
52
53 (Children's Cancer Institute Australia), Rodney Scott (University of Newcastle), John Attia
54
55
56
57
58
59
60

1
2
3 (University of Newcastle), Murray Norris (Children's Cancer Institute Australia), Carol Bower
4 (TICHR), Nicholas de Klerk (TICHR), Lin Fritschi (WA Institute for Medical Research, WAIMR),
5 Ursula Kees (TICHR), Margaret Miller (Edith Cowan University), Judith Thompson (WA Cancer
6 Registry) were the research investigators, and Helen Bailey (TICHR) was the project
7
8
9
10
11 coordinator. The clinical investigators were: Frank Alvaro (John Hunter Hospital, Newcastle);
12
13 Catherine Cole (Princess Margaret Hospital for Children, Perth); Luciano Dalla Pozza
14
15 (Children's Hospital at Westmead, Sydney); John Daubenton (Royal Hobart Hospital, Hobart);
16
17 Peter Downie (Monash Medical Centre, Melbourne); Liane Lockwood (Royal Children's
18
19 Hospital, Brisbane); Maria Kirby (Women's and Children's Hospital, Adelaide); Glenn Marshall
20
21 (Sydney Children's Hospital, Sydney); Elizabeth Smibert (Royal Children's Hospital,
22
23 Melbourne); Ram Suppiah (previously Mater Children's Hospital, Brisbane). AUS-ALL was
24
25 funded by the National Health and Medical Research Council of Australia Grant Number
26
27
28 254539.
29

30
31 **Baylor College of Medicine:** Research reported in this publication was supported by the U.S.
32
33 Department of Defense under award number CA190214 (PJ Lupo).

34
35 **California Childhood Leukemia Study:** The CCLS thanks the families for their participation
36
37 and the clinical investigators at the following collaborating hospitals for help in recruiting
38
39 patients: University of California Davis Medical Center (Dr. J. Ducore), University of California
40
41 San Francisco (Drs. M. Loh and K. Matthay), Children's Hospital of Central California (Dr. V.
42
43 Crouse), Lucile Packard Children's Hospital (Dr. G. Dahl), Children's Hospital Oakland (Dr. J.
44
45 Feusner), Kaiser Permanente Roseville (former Sacramento; Drs. K. Jolly and V. Kiley), Kaiser
46
47 Permanente Santa Clara (Drs. C. Russo, A. Wong, and D. Taggart), Kaiser Permanente San
48
49 Francisco (Dr. K. Leung), and Kaiser Permanente Oakland (Drs. D. Kronish and S. Month).
50
51 Finally, the CCLS thanks the entire study staff and former University of California, Berkeley
52
53 Survey Research Center for their effort and dedication. This work was supported by the National
54
55 Institute for Environmental Health Sciences (NIEHS) grants R01ES009137, P42ES004705,
56
57
58
59
60

1
2
3 R24ES028524, and P01ES018172, the United States Environmental Protection Agency grant
4 RD83451101, and with the additional support from the Children with Cancer UK (CWCUK). The
5 content of this manuscript is solely the responsibility of the authors and does not necessarily
6 represent the official views of the funding sponsors.
7
8
9
10

11 **NARECHEM-ST:** The authors wish to acknowledge the contribution of the network
12 (narechem.gr) of pediatric hematologists-oncologists, radiologists, immunologists, and
13 pediatricians who made this study possible; the field coordinator Evanthia Bouka,
14 MPH and the statisticians Nick Dessypris M.Sc., Ph.D and George Markozannes M.Sc., Ph.D.
15 Continuous clinical support by Margarita Baka M.D. (Department of Pediatric Hematology–
16 Oncology, “P&A Kyriakou” Children’s Hospital, Athens), Maria Moschovi M.D., Sophia
17 Polychronopoulou M.D.(Departments of Pediatric Hematology–Oncology, “A. Sophia” Children’s
18 Hospital, Athens); Emmanuel Hatzipantelis M.D., Ph.D (Pediatric Hematology Oncology Unit,
19 2nd Pediatric Department of Aristotle University, AHEPA General Hospital, Thessaloniki); Maria
20 Kourti M.D.(Pediatric Oncology Department, Hippokration Hospital, Thessaloniki); Eftychia
21 Stiakaki M.D.(Department of Pediatric Hematology-Oncology, University Hospital of Heraklion,
22 Heraklion); Maria Karalexi and Ioannis Matsoukis M.D. (Department of Hygiene, Epidemiology
23 and Medical Statistics, Athens University Medical School, 11527 Athens) should be also
24 acknowledged. The Study has been supported in part since 1996 by the Hellenic Society for
25 Social Pediatrics and Health Promotion.
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44

45 **Disclaimer**

46
47 Where authors are identified as personnel of the International Agency for Research on Cancer/
48 World Health Organization, the authors alone are responsible for the views expressed in this
49 article and they do not necessarily represent the decisions, policy or views of the International
50 Agency for Research on Cancer/ World Health Organization.
51
52
53
54
55
56
57
58
59
60

ORCID iDs

1. Philip Lupo - 0000-0003-0978-5863
2. Tiffany Chambers - 0000-0001-7618-7009
3. Beth Mueller - 0000-0003-2516-1575
4. Jacqueline Clavel - 0000-0002-3616-7676
5. John Dockerty - 0000-0002-5644-9398
6. David Doody - 0000-0003-2291-6493
7. Friederike Erdmann - 0000-0002-9982-3300
8. Sameera Ezzat - 0000-0003-3927-401X
9. Tommaso Filippini - 0000-0003-2100-0344
10. Johnni Hansen - 0000-0002-9342-2725
11. Julia Heck - 0000-0001-8713-8413
12. Claire Infante-Rivard - 0000-0003-1275-7775
13. Alice Kang - 0009-0009-8455-3481
14. Corrado Magnani - 0000-0001-6413-5471
15. Carlotta Malagoli - 0000-0002-5085-347X
16. Catherine Metayer - 0000-0003-3467-4145
17. Helen Bailey - 0000-0002-1259-3793
18. Ana Mora - 0000-0002-2008-9714
19. Evangelia Ntzani - 0000-0003-3712-4181
20. Eleni Petridou - 0000-0003-3695-3439
21. Maria Pombo-de-Oliveira - 0000-0002-1507-004X
22. Wafaa Rashed - 0000-0001-7531-2840
23. Eve Roman - 0000-0001-7603-3704
24. Joachim Schüz - 0000-0001-9687-2134
25. Catharina Wesseling - 0000-0001-5523-9981
26. Logan Spector - 0000-0003-2516-0222
27. Michael Scheurer - 0000-0002-8379-608

References

1. Johnston WT, Erdmann F, Newton R, Steliarova-Foucher E, Schuz J, Roman E. Childhood cancer: Estimating regional and global incidence. *Cancer Epidemiol* 2021;**71**: 101662.
2. Steliarova-Foucher E, Colombet M, Ries LAG, Moreno F, Dolya A, Bray F, Hesselning P, Shin HY, Stiller CA, contributors I-. International incidence of childhood cancer, 2001-10: a population-based registry study. *Lancet Oncol* 2017;**18**: 719-31.
3. Barrington-Trimis JL, Cockburn M, Metayer C, Gauderman WJ, Wiemels J, McKean-Cowdin R. Trends in childhood leukemia incidence over two decades from 1992 to 2013. *Int J Cancer* 2017;**140**: 1000-8.
4. Pui CH, Yang JJ, Hunger SP, Pieters R, Schrappe M, Biondi A, Vora A, Baruchel A, Silverman LB, Schmiegelow K, Escherich G, Horibe K, et al. Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration. *J Clin Oncol* 2015;**33**: 2938-48.
5. Hudson MM, Ness KK, Gurney JG, Mulrooney DA, Chemaitilly W, Krull KR, Green DM, Armstrong GT, Nottage KA, Jones KE, Sklar CA, Srivastava DK, et al. Clinical ascertainment of health outcomes among adults treated for childhood cancer. *Jama* 2013;**309**: 2371-81.
6. Zhang J, Walsh MF, Wu G, Edmonson MN, Gruber TA, Easton J, Hedges D, Ma X, Zhou X, Yergeau DA, Wilkinson MR, Vadodaria B, et al. Germline Mutations in Predisposition Genes in Pediatric Cancer. *The New England journal of medicine* 2015;**373**: 2336-46.
7. Buitenkamp TD, Izraeli S, Zimmermann M, Forestier E, Heerema NA, van den Heuvel-Eibrink MM, Pieters R, Korbijn CM, Silverman LB, Schmiegelow K, Liang DC, Horibe K, et al. Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group. *Blood* 2014;**123**: 70-7.
8. Krivit W, Good RA. Simultaneous occurrence of mongolism and leukemia; report of a nationwide survey. *AMA J Dis Child* 1957;**94**: 289-93.

1
2
3 9. Marlow EC, Ducore J, Kwan ML, Cheng SY, Bowles EJA, Greenlee RT, Pole JD,
4
5 Rahm AK, Stout NK, Weinmann S, Smith-Bindman R, Miglioretti DL. Leukemia Risk in a Cohort
6
7 of 3.9 Million Children with and without Down Syndrome. *The Journal of pediatrics* 2021;**234**:
8
9 172-80 e3.
10

11 10. Lupo PJ, Schraw JM, Desrosiers TA, Nembhard WN, Langlois PH, Canfield MA,
12
13 Copeland G, Meyer RE, Brown AL, Chambers TM, Sok P, Danysh HE, et al. Association
14
15 Between Birth Defects and Cancer Risk Among Children and Adolescents in a Population-
16
17 Based Assessment of 10 Million Live Births. *JAMA Oncol* 2019;**5**: 1150-8.
18

19 11. Christianson A, Howson C, Modell B, Global Report on Birth Defects: The Hidden
20
21 Toll of Dying and Disabled Children, 2006.
22

23 12. Agha MM, Williams JI, Marrett L, To T, Zipursky A, Dodds L. Congenital
24
25 abnormalities and childhood cancer. *Cancer* 2005;**103**: 1939-48.
26

27 13. Altmann AE, Halliday JL, Giles GG. Associations between congenital malformations
28
29 and childhood cancer. A register-based case-control study. *British Journal of Cancer* 1998;**78**:
30
31 1244-9.
32

33 14. Bjorge T, Cnattingius S, Lie RT, Tretli S, Engeland A. Cancer risk in children with
34
35 birth defects and in their families: a population based cohort study of 5.2 million children from
36
37 Norway and Sweden. *Cancer epidemiology, biomarkers & prevention : a publication of the*
38
39 *American Association for Cancer Research, cosponsored by the American Society of*
40
41 *Preventive Oncology* 2008;**17**: 500-6.
42

43 15. Botto LD, Flood T, Little J, Fluchel MN, Krikov S, Feldkamp ML, Wu Y, Goedken R,
44
45 Puzhankara S, Romitti PA. Cancer risk in children and adolescents with birth defects: a
46
47 population-based cohort study. *PLoS One* 2013;**8**: e69077.
48
49

50 16. Carozza SE, Bae H, Meath T, Branscum A, Bovbjerg ML, Langlois PH. Evaluation of
51
52 maternal health and labor and delivery conditions as risk factors for childhood leukemias in
53
54 children with Down syndrome. *Cancer Epidemiol* 2017;**46**: 36-41.
55
56
57
58
59
60

- 1
2
3 17. Daltveit DS, Klungsoyr K, Engeland A, Ekbohm A, Gissler M, Glimelius I, Grotmol T,
4 Madanat-Harjuoja L, Ording AG, Saether SMM, Sorensen HT, Troisi R, et al. Cancer risk in
5 individuals with major birth defects: large Nordic population based case-control study among
6 children, adolescents, and adults. *BMJ* 2020;**371**: m4060.
7
8
9
10
11 18. Dawson S, Charles AK, Bower C, de Klerk NH, Milne E. Risk of cancer among
12 children with birth defects: a novel approach. *Birth defects research Part A, Clinical and*
13 *molecular teratology* 2015;**103**: 284-91.
14
15
16
17 19. Fisher PG, Reynolds P, Von Behren J, Carmichael SL, Rasmussen SA, Shaw GM.
18 Cancer in children with nonchromosomal birth defects. *The Journal of pediatrics* 2012;**160**: 978-
19 83.
20
21
22
23 20. Janitz AE, Neas BR, Campbell JE, Pate AE, Stoner JA, Magzamen SL, Peck JD.
24 Childhood cancer in children with congenital anomalies in Oklahoma, 1997 to 2009. *Birth*
25 *defects research Part A, Clinical and molecular teratology* 2016;**106**: 633-42.
26
27
28
29 21. Johnson KJ, Lee JM, Ahsan K, Padda H, Feng Q, Partap S, Fowler SA, Druley TE.
30 Pediatric cancer risk in association with birth defects: A systematic review. *PLoS One* 2017;**12**:
31 e0181246.
32
33
34
35 22. Narod SA, Hawkins MM, Robertson CM, Stiller CA. Congenital anomalies and
36 childhood cancer in Great Britain. *American journal of human genetics* 1997;**60**: 474-85.
37
38
39
40 23. Norwood MS, Lupo PJ, Chow EJ, Scheurer ME, Plon SE, Danysh HE, Spector LG,
41 Carozza SE, Doody DR, Mueller BA. Childhood cancer risk in those with chromosomal and non-
42 chromosomal congenital anomalies in Washington State: 1984-2013. *PLoS One* 2017;**12**:
43 e0179006.
44
45
46
47 24. Rankin J, Silf KA, Pearce MS, Parker L, Ward Platt M. Congenital anomaly and
48 childhood cancer: A population-based, record linkage study. *Pediatric blood & cancer* 2008;**51**:
49 608-12.
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 25. Metayer C, Milne E, Clavel J, Infante-Rivard C, Petridou E, Taylor M, Schuz J,
4 Spector LG, Dockerty JD, Magnani C, Pombo-de-Oliveira MS, Sinnett D, et al. The Childhood
5 Leukemia International Consortium. *Cancer Epidemiol* 2013;**37**: 336-47.
6
7
8
9 26. Bailey HD, Fritschi L, Infante-Rivard C, Glass DC, Miligi L, Dockerty JD, Lightfoot T,
10 Clavel J, Roman E, Spector LG, Kaatsch P, Metayer C, et al. Parental occupational pesticide
11 exposure and the risk of childhood leukemia in the offspring: findings from the childhood
12 leukemia international consortium. *Int J Cancer* 2014;**135**: 2157-72.
13
14
15
16
17 27. Karalexi MA, Dessypris N, Clavel J, Metayer C, Erdmann F, Orsi L, Kang AY, Schuz
18 J, Bonaventure A, Greenop KR, Milne E, Petridou ET, et al. Coffee and tea consumption during
19 pregnancy and risk of childhood acute myeloid leukemia: A Childhood Leukemia International
20 Consortium (CLIC) study. *Cancer Epidemiol* 2019;**62**: 101581.
21
22
23
24
25 28. Karalexi MA, Dessypris N, Ma X, Spector LG, Marcotte E, Clavel J, Pombo-de-
26 Oliveira MS, Heck JE, Roman E, Mueller BA, Hansen J, Auvinen A, et al. Age-, sex- and
27 disease subtype-related foetal growth differentials in childhood acute myeloid leukaemia risk: A
28 Childhood Leukemia International Consortium analysis. *Eur J Cancer* 2020;**130**: 1-11.
29
30
31
32
33 29. Marcotte EL, Thomopoulos TP, Infante-Rivard C, Clavel J, Petridou ET, Schuz J,
34 Ezzat S, Dockerty JD, Metayer C, Magnani C, Scheurer ME, Mueller BA, et al. Caesarean
35 delivery and risk of childhood leukaemia: a pooled analysis from the Childhood Leukemia
36 International Consortium (CLIC). *Lancet Haematol* 2016;**3**: e176-85.
37
38
39
40
41
42 30. Metayer C, Petridou E, Arangure JM, Roman E, Schuz J, Magnani C, Mora AM,
43 Mueller BA, de Oliveira MS, Dockerty JD, McCauley K, Lightfoot T, et al. Parental Tobacco
44 Smoking and Acute Myeloid Leukemia: The Childhood Leukemia International Consortium. *Am*
45 *J Epidemiol* 2016;**184**: 261-73.
46
47
48
49
50
51 31. Panagopoulou P, Skalkidou A, Marcotte E, Erdmann F, Ma X, Heck JE, Auvinen A,
52 Mueller BA, Spector LG, Roman E, Metayer C, Magnani C, et al. Parental age and the risk of
53
54
55
56
57
58
59
60

1
2
3 childhood acute myeloid leukemia: results from the Childhood Leukemia International
4 Consortium. *Cancer Epidemiol* 2019;**59**: 158-65.

5
6
7 32. Government of Western Australia Department of Health. WARDA – Diagnostic codes
8 for birth defects.

9
10
11 33. Mai CT, Isenburg JL, Canfield MA, Meyer RE, Correa A, Alverson CJ, Lupo PJ,
12 Riehle-Colarusso T, Cho SJ, Aggarwal D, Kirby RS, National Birth Defects Prevention N.
13 National population-based estimates for major birth defects, 2010-2014. *Birth Defects Res*
14 2019;**111**: 1420-35.

15
16
17 34. Yoon PW, Rasmussen SA, Lynberg MC, Moore CA, Anderka M, Carmichael SL,
18 Costa P, Druschel C, Hobbs CA, Romitti PA, Langlois PH, Edmonds LD. The National Birth
19 Defects Prevention Study. *Public Health Rep* 2001;**116 Suppl 1**: 32-40.

20
21
22 35. Benjamini Y, Drai D, Elmer G, Kafkafi N, Golani I. Controlling the false discovery rate
23 in behavior genetics research. *Behav Brain Res* 2001;**125**: 279-84.

24
25
26 36. Mai CT, Isenburg J, Langlois PH, Alverson CJ, Gilboa SM, Rickard R, Canfield MA,
27 Anjohrin SB, Lupo PJ, Jackson DR, Stallings EB, Scheuerle AE, et al. Population-based birth
28 defects data in the United States, 2008 to 2012: Presentation of state-specific data and
29 descriptive brief on variability of prevalence. *Birth defects research Part A, Clinical and*
30 *molecular teratology* 2015;**103**: 972-93.

31
32
33 37. Reefhuis J, Gilboa SM, Anderka M, Browne ML, Feldkamp ML, Hobbs CA, Jenkins
34 MM, Langlois PH, Newsome KB, Olshan AF, Romitti PA, Shapira SK, et al. The National Birth
35 Defects Prevention Study: A review of the methods. *Birth defects research Part A, Clinical and*
36 *molecular teratology* 2015;**103**: 656-69.

37
38
39 38. Rutkowski RE, Salemi JL, Tanner JP, Matas JL, Kirby RS. Assessing the Impact of
40 Different Race-Bridging Algorithms on the Reported Rate of Birth Defects. *J Registry Manag*
41 2017;**44**: 146-56.

1
2
3 39. Salemi JL, Tanner JP, Sampat DP, Rutkowski RE, Anjohrin SB, Marshall J, Kirby
4 RS. Evaluation of the Sensitivity and Accuracy of Birth Defects Indicators on the 2003 Revision
5 of the U.S. Birth Certificate: Has Data Quality Improved? *Paediatr Perinat Epidemiol* 2017;**31**:
6 67-75.
7
8
9

10
11 40. Heinke D, Isenburg JL, Stallings EB, Short TD, Le M, Fisher S, Shan X, Kirby RS,
12 Nguyen HH, Nestoridi E, Nembhard WN, Romitti PA, et al. Prevalence of structural birth defects
13 among infants with Down syndrome, 2013-2017: A US population-based study. *Birth Defects*
14 *Res* 2021;**113**: 189-202.
15
16
17

18
19 41. Brown AL, de Smith AJ, Gant VU, Yang W, Scheurer ME, Walsh KM, Chernus JM,
20 Kallsen NA, Peyton SA, Davies GE, Ehli EA, Winick N, et al. Inherited genetic susceptibility to
21 acute lymphoblastic leukemia in Down syndrome. *Blood* 2019;**134**: 1227-37.
22
23
24

25
26 42. Walsh MF, Chang VY, Kohlmann WK, Scott HS, Cunniff C, Bourdeaut F, Molenaar
27 JJ, Porter CC, Sandlund JT, Plon SE, Wang LL, Savage SA. Recommendations for Childhood
28 Cancer Screening and Surveillance in DNA Repair Disorders. *Clin Cancer Res* 2017;**23**: e23-
29 e31.
30
31
32

33
34 43. Luke B, Brown MB, Nichols HB, Schymura MJ, Browne ML, Fisher SC, Forestieri
35 NE, Rao C, Yazdy MM, Gershman ST, Ethen MK, Canfield MA, et al. Assessment of Birth
36 Defects and Cancer Risk in Children Conceived via In Vitro Fertilization in the US. *JAMA Netw*
37 *Open* 2020;**3**: e2022927.
38
39
40

41
42 44. Lupo PJ, Spector LG. Cancer Progress and Priorities: Childhood Cancer. *Cancer*
43 *epidemiology, biomarkers & prevention : a publication of the American Association for Cancer*
44 *Research, cosponsored by the American Society of Preventive Oncology* 2020;**29**: 1081-94.
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. Demographics of Subjects from the Childhood Cancer and Leukemia International Consortium

	Controls (N=46,172)	Cases (N=15,235)	ALL^a (N=13,115)	AML^b (N=2,120)	Infant^c (N=1,152)
Study Site					
Australia (Aus-ALL)	1,246 (2.7)	387 (2.5)	387 (2.6)	0 (0.0)	10 (0.9)
Brazil	541 (1.3)	578 (3.8)	428 (3.2)	150 (7.1)	135 (11.7)
Canada	790 (1.7)	753 (4.9)	753 (5.7)	0 (0.0)	24 (2.1)
Costa Rica	578 (1.2)	291 (1.9)	251 (1.9)	40 (1.9)	13 (1.1)
Denmark	15,871 (34.4)	1,582 (10.4)	1,333 (10.1)	249 (11.8)	86 (7.5)
Egypt	351 (0.8)	296 (1.9)	296 (2.2)	0 (0.0)	5 (0.4)
France (Adele)	288 (0.6)	275 (1.8)	240 (1.8)	35 (1.7)	16 (1.4)
France (Electre)	567 (1.2)	458 (3.0)	399 (3.0)	59 (2.8)	11 (0.9)
France (Escale)	1,681 (3.6)	738 (4.8)	641 (4.8)	97 (4.6)	29 (2.5)
France (Estelle)	1,420 (3.1)	727 (4.8)	628 (4.7)	99 (4.7)	34 (2.9)
Germany	2,056 (4.5)	720 (4.7)	622 (4.7)	98 (4.6)	44 (3.8)
Greece (NARECHEM-ST)	1,433 (3.1)	1,297 (8.5)	1,233 (9.3)	64 (3.0)	41 (3.6)
Italy (MORE)	528 (1.1)	110 (0.7)	106 (0.8)	4 (0.2)	7 (0.6)
Italy (SETIL)	1,044 (2.2)	677 (4.4)	596 (4.5)	81 (3.8)	30 (2.6)
New Zealand (NZCCS)	303 (0.7)	118 (0.8)	96 (0.7)	22 (1.0)	5 (0.4)
United Kingdom (UKCCS)	7,610 (16.5)	1,672 (11.0)	1,437 (10.9)	235 (11.1)	90 (7.8)
USA (California Childhood Leukemia Study)	1,225 (2.7)	944 (6.2)	813 (6.1)	131 (6.2)	45 (3.9)
USA (Children's Cancer Group)	2,596 (5.6)	2,428 (15.9)	1,911 (14.4)	517 (24.3)	34 (2.9)
USA (Children's Cancer Group – AE24)	324 (0.7)	433 (2.8)	262 (2.0)	171 (8.0)	440 (38.2)
USA (Texas)	426 (0.9)	347 (2.3)	334 (3.3)	13 (0.8)	35 (3.0)
USA (Washington)	5,294 (11.5)	404 (2.7)	349 (2.6)	55 (2.6)	18 (1.6)
Sex					
Male	24,909 (53.9)	8,380 (55.0)	7,283 (55.5)	1,097 (51.8)	563 (48.9)
Female	21,262 (46.1)	6,854 (45.0)	5,831 (44.5)	1,023 (48.2)	589 (51.1)
Missing	1	1	1	0	0
Birthweight (in grams)					
<2500 grams	2,515 (5.9)	768 (5.2)	659 (5.2)	109 (5.3)	55 (4.9)
2500-3999 grams	34,835 (81.0)	11,927 (81.1)	10,241 (80.9)	1,686 (82.3)	915 (81.7)
>3999 grams	5,636 (13.1)	2,009 (13.7)	1,756 (13.9)	253 (12.4)	150 (13.4)
Missing	3,186	531	459	72	32
Maternal Age					
<25 years	12,410 (27.2)	4,170 (27.7)	3,522 (27.2)	648 (30.8)	295 (26.4)
25-29 years	16,268 (35.6)	5,147 (34.2)	4,431 (34.3)	716 (34.0)	341 (30.5)
30-34 years	11,647 (25.5)	3,907 (26.0)	3,408 (26.3)	499 (23.7)	324 (28.9)
35-39 years	4,52 (9.9)	1,516 (10.1)	1,314 (10.2)	202 (9.6)	129 (11.5)
≥40 years	872 (1.9)	303 (2.0)	264 (2.0)	39 (1.9)	31 (2.8)
Missing	473	192	176	16	32
Child Race/Ethnicity					

	Controls (N=46,172)	Cases (N=15,235)	ALL^a (N=13,115)	AML^b (N=2,120)	Infant^c (N=1,152)
Non-Hispanic White	38,145 (89.3)	11,247 (80.5)	9,644 (80.6)	1,603 (79.8)	810 (76.0)
Non-Hispanic Black	718 (1.7)	350 (2.5)	269 (2.3)	81 (4.0)	60 (5.6)
Hispanic	1,693 (4.0)	1,207 (8.6)	1,036 (8.7)	171 (8.5)	114 (10.7)
Other	2,181 (5.1)	1,170 (8.4)	1,015 (8.5)	155 (7.7)	82 (7.7)
Missing	3,435	1,261	1,151	110	86
Gestational Age^d					
Preterm	2,425 (6.4)	952 (7.3)	827 (7.4)	125 (6.7)	68 (6.7)
Term	35,421 (93.6)	12,047 (92.7)	10,295 (92.6)	1,752 (93.3)	942 (93.3)
Missing	8,326	2,236	1,993	243	142
Maternal Education					
Less than Secondary Education	7,471 (30.1)	4,042 (32.2)	3,499 (32.3)	543 (31.6)	231 (22.9)
Completed Secondary Education	9,360 (37.7)	4,289 (34.2)	3,586 (33.1)	703 (40.9)	292 (28.9)
Above Secondary Education	7,983 (32.2)	4,227 (33.7)	3,752 (34.6)	475 (27.6)	489 (48.3)
Missing	21,358	2,677	2,278	399	140
Plurality					
Singleton	42,740 (96.8)	13,423 (95.9)	11,541 (95.5)	1,882 (98.5)	944 (97.4)
Multiple	1,408 (3.2)	568 (4.1)	539 (4.5)	29 (1.5)	25 (2.6)
Missing	2,024	1,244	1,035	209	183
Age at Dx./Inclusion (Mean/SD)	5.7 (4.2)	5.5 (4.0)	5.4 (3.7)	6.2 (5.3)	0.5 (0.4)

^aAcute lymphoblastic leukemia

^bAcute myeloid leukemia

^cInfant leukemia includes any leukemia case diagnosed at ≤12 months of age

^dPreterm: <37 weeks; Term: ≥37 weeks

Table 2. Risk of Childhood Leukemia by Birth Defect Group and Leukemia Subtype

	ALL ^a						AML ^b					Infant ^c				
	Controls N=46,172	Cases N=13,115					Cases N=2,120					Cases N=1,152				
	Exposed N=2,662	Exposed N=753	Unadjust ed OR* (95% CI)	Adjusted OR* (95% CI)	p	p ^{FDR}	Exposed N=129	Unadjust ed OR* (95% CI)	Adjusted OR* (95% CI)	p	p ^{FDR}	Exposed N=124	Unadjust ed OR* (95% CI)	Adjusted OR* (95% CI)	p	p ^{FDR}
Congenital anomalies of the nervous system	49 (1.8)	13 (1.7)	0.93 (0.51-1.72)	1.60 (0.77-3.31)	0.207	0.570	5 (3.9)	2.23 (0.89-5.59)	4.23 (1.50-11.89)	0.006	0.024	3 (2.4)	--	--	--	--
Congenital anomalies of the eye	73 (2.7)	31 (4.1)	1.50 (0.98-2.28)	1.55 (0.93-2.58)	0.095	0.299	5 (3.9)	1.49 (0.60-3.70)	1.75 (0.65-4.59)	0.258	0.387	2 (1.6)	--	--	--	--
Anophthalmia or microphthalmia	25 (1.0)	6 (0.7)	0.84 (0.35-2.06)	0.58 (0.17-1.98)	0.384	0.590	1 (0.8)	--	--	--	--	0 (0.0)	--	--	--	--
Congenital cataract	3 (0.1)	7 (0.9)	8.22 (2.12-31.79)	18.62 (4.36-79.49)	<0.001	0.002	0 (0.0)	--	--	--	--	0 (0.0)	--	--	--	--
Congenital anomalies of the ear, face and neck	241 (9.1)	30 (3.9)	0.44 (0.30-0.64)	0.91 (0.57-1.45)	0.684	0.836	6 (4.7)	0.54 (0.24-1.22)	1.28 (0.54-3.02)	0.570	0.664	5 (4.1)	0.83 (0.34-2.02)	1.27 (0.38-4.23)	0.700	0.900
Congenital anomalies of the respiratory system	39 (1.5)	9 (0.1)	0.81 (0.39-1.68)	0.93 (0.34-2.58)	0.894	0.790	3 (2.3)	--	--	--	--	3 (2.4)	--	--	--	--
Congenital anomalies of the heart and circulatory system	408 (15.3)	129 (17.1)	1.11 (0.91-1.36)	1.46 (1.10-1.95)	0.009	0.050	31 (24.0)	1.66 (1.15-2.40)	2.86 (1.81-4.52)	<0.001	0.001	16 (13.0)	1.58 (0.96-2.61)	1.57 (0.75-3.27)	0.227	0.681
<i>Right ventricular outflow tract defects</i>	123 (4.6)	60 (7.9)	1.72 (1.26-2.34)	0.72 (0.35-1.48)	0.366	0.590	10 (7.8)	1.77 (0.93-3.39)	1.30 (0.47-3.59)	0.608	0.664	8 (6.5)	2.62 (1.28-5.37)	1.35 (0.38-4.74)	0.641	0.900
Pulmonary valve atresia and stenosis	122 (4.6)	60 (7.9)	1.73 (1.27-2.36)	0.73 (0.35-1.50)	0.381	0.590	10 (7.8)	1.79 (0.94-3.41)	1.32 (0.48-3.64)	0.594	0.664	8 (6.5)	2.64 (1.29-5.41)	1.40 (0.39-4.98)	0.605	0.900
<i>Septal defects</i>	90 (3.4)	15 (2.0)	0.59 (0.34-1.01)	1.11 (0.60-2.04)	0.743	0.861	5 (3.9)	1.21 (0.49-2.98)	2.37 (0.85-6.66)	0.100	0.172	1 (0.8)	--	--	--	--
Ventricular septal defect	63 (2.4)	7 (0.9)	0.39 (0.18-0.85)	0.68 (0.30-1.56)	0.359	0.590	1 (0.8)	--	--	--	--	1 (0.8)	--	--	--	--

			ALL ^a				AML ^b					Infant ^c				
	Controls N=46,172	Cases N=13,115					Cases N=2,120					Cases N=1,152				
	Exposed N=2,662	Exposed N=753	Unadjusted OR* (95% CI)	Adjusted OR* (95% CI)	p	p ^{FDR}	Exposed N=129	Unadjusted OR* (95% CI)	Adjusted OR* (95% CI)	p	p ^{FDR}	Exposed N=124	Unadjusted OR* (95% CI)	Adjusted OR* (95% CI)	p	p ^{FDR}
Atrial septal defect	35 (1.3)	8 (1.0)	0.80 (0.37-1.73)	2.17 (0.89-5.25)	0.090	0.299	4 (3.1)	--	--	--	--	0 (0.0)	--	--	--	--
Cleft palate and cleft lip	70 (2.6)	13 (1.7)	0.65 (0.36-1.18)	0.71 (0.34-1.22)	0.348	0.590	2 (1.6)	--	--	--	--	0 (0.0)	--	--	--	--
Cleft palate without cleft lip	35 (1.3)	10 (1.3)	1.01 (0.50-2.03)	0.70 (0.29-1.62)	0.402	0.590	2 (1.6)	--	--	--	--	0 (0.0)	--	--	--	--
Congenital anomalies of the digestive system	48 (1.8)	25 (3.3)	1.84 (1.13-2.98)	2.70 (1.46-4.98)	0.002	0.022	5 (3.9)	2.27 (0.90-5.71)	3.09 (0.97-9.91)	0.057	0.114	6 (4.9)	5.03 (2.15-11.78)	4.55 (1.06-19.62)	0.042	0.378
Congenital anomalies of the genitourinary system	623 (23.4)	123 (16.3)	0.69 (0.57-0.84)	1.00 (0.78-1.27)	0.979	0.979	28 (21.7)	0.98 (0.67-1.43)	1.60 (1.02-2.51)	0.041	0.099	17 (13.8)	1.10 (0.67-1.78)	0.84 (0.40-1.76)	0.645	0.900
Renal agenesis and hypoplasia	71 (2.7)	35 (4.6)	1.74 (1.16-2.61)	1.20 (0.64-2.25)	0.572	0.787	6 (4.7)	1.84 (0.80-4.25)	0.75 (0.16-3.51)	0.719	0.719	5 (4.1)	2.83 (1.14-7.02)	0.76 (0.09-6.59)	0.804	0.905
Obstructive genitourinary defects	43 (1.6)	9 (1.1)	0.74 (0.36-1.51)	1.23 (0.55-2.74)	0.610	0.790	2 (1.6)	--	--	--	--	1 (0.8)	--	--	--	--
Hypospadias	57 (2.1)	18 (2.4)	1.08 (0.64-1.84)	2.12 (1.16-3.85)	0.015	0.066	0 (0.0)	--	--	--	--	0 (0.0)	--	--	--	--
Congenital anomalies of the musculoskeletal system	461 (17.3)	92 (12.2)	0.70 (0.56-0.88)	0.88 (0.66-1.17)	0.381	0.590	10 (7.8)	0.47 (0.25-0.88)	0.42 (0.18-0.97)	0.041	0.099	6 (4.9)	0.52 (0.23-1.16)	0.44 (0.16-1.18)	0.101	0.455
Congenital hip dislocation	79 (3.0)	12 (1.6)	0.53 (0.29-0.98)	1.01 (0.51-2.02)	0.967	0.979	1 (0.8)	--	--	--	--	1 (0.8)	--	--	--	--
Congenital anomalies of the skin	221 (8.3)	135 (17.9)	2.16 (1.74-2.68)	1.43 (1.11-1.85)	0.006	0.044	16 (12.4)	1.58 (0.95-2.63)	0.36 (0.18-0.70)	0.003	0.018	32 (26.0)	5.94 (4.08-8.65)	1.02 (0.54-1.90)	0.959	0.959

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

*Adjusted for study site, sex, maternal age, birth year, birthweight, prematurity, and race/ethnicity

^aAcute lymphoblastic leukemia

^bAcute myeloid leukemia

^cInfant leukemia includes any leukemia case diagnosed at ≤ 12 months of age

For Peer Review

Table 3. Risk of ALL^a by Birth Defect Group and Study Design

	Registry-Based Studies					Questionnaire-Based Studies				
	Controls N=21,693	Cases N=1,788				Controls N=24,479	Cases N=11,327			
	Exposed N=1,623	Exposed N=186	Unadjusted OR (95% CI)	Adjusted OR* (95% CI)	p	Exposed N=1,039	Exposed N=567	Unadjusted OR (95% CI)	Adjusted OR* (95% CI)	p
Congenital anomalies of the nervous system	32 (2.0)	7 (3.8)	3.22 (1.58-6.56)	2.30 (0.88-6.05)	0.089	17 (1.6)	6 (1.1)	0.87 (0.37-2.01)	1.13 (0.41-3.09)	0.815
Congenital cataract	2 (0.1)	6 (3.2)	30.88 (6.23-153.11)	31.85 (6.10-166.17)	<0.001	1 (0.1)	1 (0.2)	--	--	--
Congenital anomalies of the heart and circulatory system	239 (14.7)	44 (23.7)	2.62 (1.97-3.49)	2.36 (1.66-3.35)	<0.001	169 (16.3)	85 (15.0)	1.16 (0.91-1.48)	0.84 (0.55-1.28)	0.418
Congenital anomalies of the digestive system	27 (16.6)	10 (5.4)	4.20 (2.08-8.48)	3.88 (1.63-9.19)	0.002	21 (2.0)	15 (2.6)	1.75 (0.95-3.23)	2.00 (0.89-4.52)	0.094
Congenital anomalies of the genitourinary system	445 (27.4)	41 (22.0)	1.18 (0.88-1.58)	1.08 (0.76-1.54)	0.656	178 (17.1)	82 (14.5)	1.05 (0.82-1.34)	0.92 (0.66-1.28)	0.724
Hypospadias	36 (2.2)	8 (4.3)	2.29 (1.06-4.93)	2.92 (1.33-6.40)	0.007	21 (2.0)	10 (1.8)	0.92 (0.45-1.90)	1.50 (0.64-3.53)	0.356
Congenital anomalies of the musculoskeletal system	169 (10.4)	18 (9.7)	1.26 (0.90-1.76)	1.23 (0.83-1.82)	0.295	142 (13.7)	57 (10.1)	0.84 (0.63-1.13)	0.66 (0.44-0.99)	0.046
Congenital anomalies of the skin	86 (5.2)	15 (8.1)	1.92 (1.12-3.27)	1.83 (0.97-3.48)	0.063	135 (13.0)	120 (21.2)	1.85 (1.46-2.35)	1.36 (1.04-1.80)	0.025

*Adjusted for study site, sex, maternal age, birth year, birthweight, prematurity, and race/ethnicity

^aAcute lymphoblastic leukemia

Table 4. Risk of AML^a by Birth Defect Group and Study Design

	Registry-Based Studies					Questionnaire-Based Studies				
	Controls N=21,693	Cases N=308				Controls N=24,479	Cases N=1,812			
	Exposed N=1,623	Exposed N=40	Unadjusted OR* (95% CI)	Adjusted OR* (95% CI)	p	Exposed N=1,039	Exposed N=89	Unadjusted OR* (95% CI)	Adjusted OR* (95% CI)	p
Congenital anomalies of the nervous system	32 (2.0)	3 (7.5)	--	--	--	17 (1.6)	2 (2.2)	--	--	--
Congenital cataract	2 (0.1)	0 (0.0)	--	--	--	1 (0.1)	0 (0.0)	--	--	--
Congenital anomalies of the heart and circulatory system	239 (14.7)	16 (40.0)	2.62 (1.99-3.49)	5.39 (3.14-9.24)	<0.001	169 (16.3)	15 (16.9)	1.16 (0.91-1.48)	1.28 (0.61-2.67)	0.514
Congenital anomalies of the digestive system	27 (16.6)	1 (2.5)	--	--	--	21 (2.0)	4 (4.5)	--	--	--
Congenital anomalies of the genitourinary system	445 (27.4)	10 (25)	1.18 (0.88-1.58)	1.73 (0.87-3.45)	0.118	178 (17.1)	18 (20.2)	1.05 (0.81-1.34)	1.58 (0.86-2.88)	0.139
Hypospadias	36 (2.2)	0 (0.0)	--	--	--	21 (2.0)	0 (0.0)	--	--	--
Congenital anomalies of the musculoskeletal system	169 (10.4)	4 (10)	--	--	--	142 (13.7)	6 (6.7)	0.84 (0.63-1.13)	0.28 (0.85-0.91)	0.035
Congenital anomalies of the skin	86 (5.2)	1 (2.5)	--	--	--	135 (13.0)	15 (16.9)	1.85 (1.46-2.35)	0.42 (0.22-0.79)	0.007

*Adjusted for study site, sex, maternal age, birth year, birthweight, gestational age, and race/ethnicity

^aAcute myeloid leukemia

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Table 5. Risk of Childhood Leukemia by Number of Birth Defects and Leukemia Subtype

	ALL ^a					AML ^b				Infant ^c			P _{trend}
	Controls (n=46,172)	Cases (n=13,115)	Unadjusted OR* (95% CI)	Adjusted OR* (95% CI)	P _{trend}	Cases (n=2,120)	Unadjusted OR* (95% CI)	Adjusted OR* (95% CI)	P _{trend}	Cases (n=1,152)	Unadjusted OR* (95% CI)	Adjusted OR* (95% CI)	
No Defects	43,510 (94.2)	12,362 (94.3)	1.00 (Ref)	1.00 (Ref)		1,991 (93.9)	1.00 (Ref)	1.00 (Ref)		1,028 (89.2)	1.00 (Ref)	1.00 (Ref)	
1 Defect	2,436 (5.3)	704 (5.4)	1.01 (0.93-1.10)	1.15 (1.03-1.28)	0.006	108 (5.1)	1.01 (0.93-1.10)	0.92 (0.72-1.18)	0.442	94 (8.2)	1.63 (1.31-2.02)	0.97 (0.69-1.35)	0.270
≥2 Defects	226 (0.5)	49 (0.4)	0.96 (0.73-1.25)	1.32 (0.90-1.94)		21 (1.0)	0.96 (0.73-1.24)	1.96 (1.10-3.46)		30 (2.6)	5.62 (3.82-8.26)	1.71 (0.93-1.35)	

*Adjusted for study site, sex, maternal age, birth year, birthweight, prematurity, and race/ethnicity

^aAcute lymphoblastic leukemia

^bAcute myeloid leukemia

^cInfant leukemia includes any leukemia case diagnosed at ≤12 months of age